Erasca, Inc.
NASDAQ:ERASBiotechnology
Healthcare
$13.76 -0.14%
-$0.02 today
- Market cap
- $4.83B
- Beta
- 0.73
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.91
52W Low $1.21High $24.28
Volume 8.94M
Average 6.79M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$95.45M
FY 2025 · Annual
Investing Cash Flow
$100.42M
FY 2025 · Annual
Financing Cash Flow
$1.10M
FY 2025 · Annual
-99.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (122.76M) | (242.81M) | (125.04M) | (161.65M) | (124.55M) |
| Depreciation & Amortization | 829K | 2.64M | 3.73M | 3.81M | 3.11M |
| Deferred Income Tax | (1.51M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.33M | 20.11M | 26.23M | 26.97M | 24.9M |
| Change in Working Capital | 7.71M | 15.79M | 813K | 1.74M | (3.33M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.34M | 676K | (886K) | (1.53M) | 513K |
| Other Working Capital | 6.36M | 15.11M | 1.7M | 3.27M | (3.84M) |
| Other Non-Cash Items | 27.81M | 101.01M | (6.95M) | 19.72M | 4.41M |
| Operating Cash Flow | (79.6M) | (103.26M) | (101.22M) | (109.42M) | (95.46M) |
| Capital Expenditures | (18.89M) | (16.55M) | (1.78M) | (22.56M) | (128K) |
| Acquisitions (Net) | 7.68M | 4M | 0 | 0 | 0 |
| Purchases of Investments | (105.82M) | (134.33M) | (314.39M) | (403.38M) | (150.97M) |
| Sales of Investments | 60.11M | 79.8M | 244.95M | 269.33M | 261.03M |
| Other Investing Activities | (7.68M) | (4M) | (20M) | (22.5M) | (9.5M) |
| Investing Cash Flow | (64.59M) | (71.08M) | (91.22M) | (156.62M) | 100.43M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 317M | 95.25M | 1.3M | 239.06M | 1.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.01M | 2.82M | 0 | 1.64M | 0 |
| Financing Cash Flow | 439.4M | 98.08M | 1.3M | 240.7M | 1.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 295.21M | (76.27M) | (191.14M) | (25.34M) | 6.07M |
| Free Cash Flow | (98.49M) | (119.82M) | (102.99M) | (131.98M) | (95.58M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$124.5M
+ D&A$3.1M
+ Stock-Based Comp$24.9M
+ Deferred Tax$0
- Working Capital-$3.3M
+ Other Non-Cash$4.4M
= Operating Cash Flow-$95.5M
- Capex-$128.0K
= Free Cash Flow-$95.6M
Analysis
FY2025 free cash flow is -$95.6M. FCF conversion is 76.7% of net income. Operating cash flow was -$95.5M, with capex of -$128.0K. The largest bridge item is Stock-Based Comp at $24.9M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 8-K | Current report | Oct 16, 2026 | |
| 8-K | Current report | Aug 24, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
Does ERAS generate free cash flow?
Erasca, Inc. (ERAS) generated -$95.58M of free cash flow in fiscal 2025.
How much operating cash flow does ERAS produce?
Operating cash flow was -$95.45M, before capital expenditures of $128,000.00.
Continue the stock analysis
Jump to another research area for this company.